$599

Lilly Acquires Protomer Technologies

Lilly announced the acquisition of Protomer Technologies for an undisclosed amount, although Lilly said the deal is valued at >$1B, including development and commercial milestones. For context, Protomer (view website) is a private biotech company developing novel drug therapies, including glucose-responsive insulin. Below, FENIX provides thoughts on the acquisition in the context of other glucose-responsive programs like Novo Nordisk’s.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.